がんの標的療法：画期的新薬とその影響

Targeted Cancer Therapies: Innovative drugs and their impact on the future of oncology

発行	Business Insights
出版日	2004年08月	商品コード	21408
ページ情報	英文 156 Pages
価格	こちらの商品の販売は終了いたしました。

概要
原文目次
関連レポート

当商品の販売は、2011年07月19日を持ちまして終了しました。

原文目次

Targeted Cancer Therapies: Innovative drugs and their impact on the future of oncology is a management report form Business Insights, this report assesses the role of targeted cancer therapies as a driver of growth in the cancer market and their future role potential. Drugs for high-severity conditions grew over the past decade at over twice the rate of drugs for low severity conditions, traditionally served by primary care blockbuster drugs. Increasingly, pharmaceutical companies are breaking into the cancer market through brands that are launched as a therapy for a minor indication and subsequently developed for other indications and first-in-line therapies. The new wave of innovation is being led by European companies and could bring about a revolution not only in cancer treatment, but across the industry as a whole.

This report provides detailed analysis of innovation in both the diagnosis and treatment of cancer and forecasts for the success of leading drugs, enabling your company to plan effective oncology strategies.

Acknowledgements
Executive summary
Beyond the blockbuster model
Emerging therapies
Therapy area analysis
Case studies
Conclusions

Chapter 1 Beyond the blockbuster model

Summary
Introduction
Beyond blockbusters - the development of targeted therapies
Declining R&D success rates
R&D spend in Europe and the US
No economies of scale in pharmaceutical R&D: The performance gap in R&D; Mergers as a driver of productivity gains
R&D pipeline and drug discovery trends
Therapeutic focus of clinical pipeline activity
Projects by therapeutic focus
Drug discovery deals
Implications of the move away from the blockbuster model

Chapter 2 Emerging therapies

Summary
IntroductionCurrent therapies
An overview of cancer treatment: The basis for targeted therapies; A promising therapeutic field; Molecularly targeted therapies; Regulatory risk-benefit evaluation vs. the use of surrogate endpoints for clinical efficacy; Efficacy criteria
Targeted therapies as a means to improving survival rates
Current treatments by type
Global analysis
Hormonal therapies
Cytotoxics
Innovative cancer therapies: Angiogenesis inhibitors; Immunostimulators; Tumor-targeted agents
Adjunct therapies
Advances in diagnosis
Introduction
Genetic counseling
OncoAssist
CeMines
Xantos Biomedicine
Advances in treatment
Pursuing biological therapies or small molecule inhibitors
From cytotoxic to cytostatic
Angiogenesis - a promising new approach to cancer treatment-
Differentiation therapy - developing HDAC inhibitors as anti-cancer drugs
Progress in oncogenics
Regional differences in access to healthcare

Chapter 3 Therapy area analysis

Summary
Introduction
Epidemiology
Current treatments: Current therapeutics; A new biologic approach for the treatment of metastatic breast cancer; Showing promise in the treatment of breast cancer; Profile: Cancer treatment in the UK; New treatments in breast cancer: predictions
Unmet needs
Key players in breast cancerColorectal cancer
Epidemiology
Current treatments: Current therapeutics; Treatment preferences in US and Europe
Unmet needs
Key players in colorectal cancer
Lung cancer
Epidemiology
Current treatments: NSCLC; SCLC; Malignant mesothelioma; Current therapeutics
Unmet needs
Key players in lung cancer
Prostate cancer
Epidemiology
Current treatments
Unmet needs
Key players in prostate cancer

Chapter 4 Case studies

Summary
Introduction
Sanofi-Aventis
Sanofi-Synthelabo: Eloxatin; Sales forecast
Aventis: development of oncology as a blockbuster franchise
Aventis?f cancer portfolio and R&D pipeline
Taxotere: Core strategies for growth; Recent and expected approvals; Taxotere as a specialty blockbuster
Roche
Introduction
R&D alliances, partnerships and acquisitions
Roche?fs cancer portfolio and R&D pipeline
Focus on new technologies and diagnostics
Tarceva: Sales forecast
Genentech
AvastinSales forecast
AstraZeneca
Iressa: Physician rating of Iressa; Sales forecast
Brief profiles
Bristol-Myers Squibb
Eli Lilly
GlaxoSmithKline
Merck KGaA
Novartis
Pfizer
Schering AG

Chapter 5 Conclusions

Challenges for development of targeted cancer therapies
Diagnostics are integral to targeted therapies
European companies will dominate targeted cancer therapies
The future of oncology
Beyond targeted medicines
Index

List of Figures

Figure 1.1: Global oncology players, 2002
Figure 1.2: From therapy to health maintenance busters
Figure 1.3: Forecast growth by blockbuster therapy area, 2002-08
Figure 1.4: Declining R&D rates
Figure 1.5: R&D spend in Europe and the US
Figure 1.6: No economies of scale in pharmaceutical R&D
Figure 1.7: Performance gap in R&D
Figure 1.8: Shareholder returns of merged and non-merged companies
Figure 1.9: Breakdown of projects by clinical phase and source of drug
Figure 1.10: Therapeutic focus of clinical pipeline activity
Figure 1.11: Breakdown of deals by therapeutic focus (September 2002 - March 2004)
Figure 1.12: Therapeutic focus of drug technology deals across the top 15 pharmaceutical
companies (September 2002 - March 2004)
Figure 1.13: The importance of specialty products in the market
Figure 1.14: Growth rates of primary care blockbuster drugs vs. specialty care drugs
Figure 2.15: 5-year survival rates in the US (1974-1999)
Figure 2.16: The global cancer market, 1998-2002
Figure 2.17: Chronology of the various cytotoxic classes
Figure 2.18: 5-year survival rate from breast cancer in various geographies
Figure 2.19: Reduction in deaths from testicular cancer
Figure 3.20: Breast cancer market opportunities
Figure 3.21: Improved quality of life by combination vs. monotherapy
Figure 3.22: Superior survival with Xeloda/Taxotere
Figure 3.23: Therapeutic strategies in prostate cancer
Figure 4.24: Recent and expected Taxotere approvals
Figure 4.25: Taxotere as a specialty blockbuster - a nichebuster
Figure 4.26: Roche?fs changing product portfolio
Figure 4.27: Roche?fs R&D ?euniverse?f
Figure 4.28: Roches business model: focus on innovation and diagnostics

List of Tables

Table 2.1: Examples of future therapies
Table 2.2: Late stage developments in cancer therapeutics (selection as at 12/03)
Table 2.3: Molecules that block angiogenesis via vEGF
Table 2.4: Angiogenesis products (other than vEGF targeting) in development
Table 3.5: Breast cancer patient epidemiology statistics, 2004
Table 3.6: Colorectal cancer patient epidemiology statistics, 2004
Table 3.7: Standard therapeutic approaches in various stages of colorectal cancer
Table 3.8: Protocols in treatment of metastatic colorectal cancer
Table 3.9: NCSLC patient epidemiology statistics, 2004
Table 3.10: SCLC patient epidemiology statistics, 2004
Table 3.11: Prostate cancer patient epidemiology statistics, 2004
Table 4.12: Eloxatin sales forecast ($m), 2005-2009
Table 4.13: Marketed cancer products for Aventis
Table 4.14: Aventis?fs oncology R&D pipeline, 2003
Table 4.15: Roche: early stage development alliances (selected)
Table 4.16: Marketed cancer products for Roche
Table 4.17: Roche?fs oncology R&D pipeline, 2003
Table 4.18: Tarceva sales forecast ($m), 2005-2009
Table 4.19: Avastin?fs clinical development program
Table 4.20: Avastin sales forecast ($m), 2005-2009
Table 4.21: Physician rating of Iressa
Table 4.22: Iressa sales forecast ($m), 2005-2009